The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFβ in prostate cancer cells

Journal of Cellular Biochemistry

Volumn 109, Issue 4, 2010, Pages 828-837

  Van Der Deen, Margaretha ^a   Akech, Jacqueline ^a   Wang, Tao ^a   FitzGerald, Thomas J ^a   Altieri, Dario C ^a   Languino, Lucia R ^a   Lian, Jane B ^a   Van Wijnen, Andre J ^a   Stein, Janet L ^a   Stein, Gary S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bone; Cell cycle; Cell signaling; Proliferation; Steroid hormone receptors

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN P57; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIBIA; TUMOR GROWTH; WESTERN BLOTTING;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEOMICS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77749321132     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22463     Document Type: Article

References (41)

1. Afzal F, Pratap J, Ito K, Ito Y, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Javed A. 2005. Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 204:63-72.
2. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen A, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. 2009. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene [Epub ahead of print].
3. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. 2009. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 23:1203-1214.
4. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC. 2004. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases associated osteolytic disease. Cancer Res 64:4506-4513.
5. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215-1223.
6. Blyth K, Cameron ER, Neil JC. 2005. The runx genes: Gain or loss of function in cancer. Nat Rev Cancer 5:376-387.
7. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. 2006. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 66: 2195-2201.
8. Brubaker KD, Vessella RL, Brown LG, Corey E. 2003. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56:13-22.
9. Buijs JT, Van der Pluijm G. 2009. Osteotropic cancers: From primary tumor to bone. Cancer Lett 273:177-193.
10. Choi J-Y, Pratap J, Javed A, Zaidi SK, Xing L, Balint E, Dalamangas S, Boyce B, van Wijnen AJ, Lian JB, Stein JL, Jones SN, Stein GS. 2001. Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA 98:8650-8655.
11. Danielpour D. 2005. Functions and regulation of transforming growth factorbeta (TGF-beta) in the prostate. Eur J Cancer 41:846-857.
12. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, Davis JN, Meyers S. 2006. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 97:1-17.
13. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ. 2005. The bone-specific expression of RUNX2 oscillates during the cell cycle to support a G1 related anti-proliferative function in osteoblasts. J Biol Chem 280:20274-20285.
14. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW. 2005. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65:2303-2313.
15. Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, Zaidi SK, Lou Y, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2008. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem 283:8412-8422.
16. Kang JS, Alliston T, Delston R, Derynck R. 2005. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J 24:2543-2555.
17. Kansara M, Thomas DM. 2007. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26:1-18.
18. Kawate H, Wu Y, Ohnaka K, Takayanagi R. 2007. Mutual transactivational repression of Runx2 and the androgen receptor by an impairment of their normal compartmentalization. J. Steroid Biochem Mol Biol 105: 46-56.
19. Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC. 2007. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 67:11263-11271.
20. Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, Lee C. 1998. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 4:1625-1630.
21. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao Y-H, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764.
22. Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X, Lieberman JR. 2003. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21:62-72.
23. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. 2005. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65:4218-4227.
24. Mitra P, Ghule PN, van der Deen M, Medina R, Xie R, Holmes WF, Ye X, Nakayama KI, Harper JW, Stein JL, Stein GS, van Wijnen AJ. 2009. CDK inhibitors selectively diminish cell cycle controlled activation of the histone H4 gene promoter by p220(NPAT) and HiNF-P. J Cell Physiol 219:438-448.
25. Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C, Soong R, Pho RW, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. 2009. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 36:153-158.
26. Paredes R, Arriagada G, Cruzat F, Olate J, van Wijnen A, Lian J, Stein G, Stein J, Montecino M. 2004. The Runx2 transcription factor plays a key role in the 1a,25-dihydroxy vitamin D3-dependent upregulation of the rat osteocalcin (OC) gene expression in osteoblastic cells. J Steroid Biochem Mol Biol 89-90:269-271.
27. Pereira BP, Zhou Y, Gupta A, Leong DT, Aung KZ, Ling L, Pho RW, GalindoM, Salto-Tellez M, Stein GS, Cool SM, van Wijnen AJ, Nathan SS. 2009. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J Cell Physiol 221:778-788.
28. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi J-Y, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 2003. Cell growth regulatory role of Runx2 during proliferative expansion of pre-osteoblasts. Cancer Res 63:5357-5362.
29. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591.
30. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. 2006. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25:589-600.
31. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2008. Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68:7795-7802.
32. San Martin IA, Varela N, Gaete M, Villegas K, Osorio M, Tapia JC, Antonelli J, Mancilla E, Pereira BP, Nathan SS, Lian JB, Stein JL, Stein GS, van Wijnen AJ, Galindo M. 2009. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfb in osteosarcoma cells. J Cell Physiol 221:560-571.
33. Shen R, Wang X, Drissi H, Liu F, O'Keefe RJ, Chen D. 2006. Cyclin d1-Cdk4 induce Runx2 ubiquitination and degradation. J Biol Chem 281:16347-16353.
34. So AI, Hurtado-Coll A, Gleave ME. 2003. Androgens and prostate cancer. World J Urol 21:325-337.
35. Song K, Wang H, Krebs TL, Kim SJ, Danielpour D. 2008. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res 68:8173-8182.
36. van der Poel HG. 2005. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer. Eur Urol 48:1051-1058.
37. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. 1996. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study. Clin Cancer Res 2:635-640.
38. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. 1998. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77:887-894.
39. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. 2002. Regulation of human osteocalcin promoter in hormoneindependent human prostate cancer cells. J Biol Chem 277:2468-2476.
40. Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2002. Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci USA 99:8048-8053.
41. Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. 2007. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 104:19861-19866.